FUNDAMENTALS · Fundamentals · US Healthcare

Shoulder Innovations (SI) Fundamentals 2026 — Revenue Analysis | SniperIQ

Shoulder Innovations (SI) is a US-listed Healthcare company in Medical - Specialties with a market capitalization of $414M, trading at

9.99 on the NYSE. This SniperIQ fundamentals page covers Shoulder Innovations's valuation, profitability (net margin -81.8%), revenue ($47M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$414M
Net Margin-81.8%
Revenue (FY25)$47M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Shoulder Innovations's market cap?

Shoulder Innovations (SI) has a market capitalization of approximately $414M, trading at

9.99 on the NYSE. Market cap moves with the live share price.

What is Shoulder Innovations's P/E ratio?

Shoulder Innovations's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Shoulder Innovations?

Shoulder Innovations runs a net profit margin of -81.8%, a gross margin of 75.5%, and an operating margin of -57.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Shoulder Innovations generate?

Shoulder Innovations reported revenue of $47M for fiscal year 2025, with net income of -$40M and earnings per share (EPS) of -1.96. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Shoulder Innovations pay a dividend?

Shoulder Innovations does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Shoulder Innovations financially healthy?

Shoulder Innovations carries a debt-to-equity ratio of 0.11x and a current ratio of 11.81x, with a market beta of -2.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Shoulder Innovations a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shoulder Innovations (SI) the key facts are: market cap $414M, revenue $47M, 52-week range 10.92-23. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Shoulder Innovations's full fundamentals live

Get Shoulder Innovations's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Puma Biotechnology (PBYI) fundamentals · Assembly Biosciences (ASMB) fundamentals · PureTech Health (PRTC) fundamentals · Kamada (KMDA) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons